According to the report, the Asia-Pacific Pancreatic Cancer Market Size was worth USD 0.38 billion in 2019 and estimated to be growing at a CAGR of 8.5 %, to reach USD 0.57 billion by 2024.
Pancreatic cancer is caused by the uncontrolled growth of cells in the pancreas. This abnormal, unrestrained growth of cells results in the formation of lumps of tissue, widely referred to as tumors. The presence of tumors prevents the normal functioning of the pancreas. The occurrence and mortality rate of pancreatic cancer is more in men than in women. It is the ninth leading cause of cancer death in Asia.
Asia-Pacific Pancreatic Cancer Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc.,
Cancer starts when cells in the body begin to grow beyond control. Pancreatic cancer starts when cells in the pancreas start to grow incessantly eventually resulting in symptoms like abdominal pain, weight loss, diarrhea, and jaundice. Apart from lifestyle dependent factors like alcohol consumption, obesity and smoking, a personal or family history of pancreatitis or old age may result in a person being affected by pancreatic cancer.
Given the insuppressible nature of pancreatic cancer, treatments often return insufficient results. This challenge is yet another barrier to the growth of this market. Technologies are yet to develop fully for the timely diagnosis of this cancer type, which results in the diagnosis of the majority of pancreatic cancer patients at an advanced stage of the disease. This explains the high mortality rates associated with pancreatic cancer. Estimates show that only a small percentage, that is about 12% to 15% of the patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.
Detailed Segmentation of the report:
By Treatment Type: Surgery, Chemotherapy, Radiation Therapy & Others
By Type: Exocrine Pancreas Cancer & Endocrine Pancreas Cancer
By End Users: Hospitals, Clinics, Research Institutes & Others
By Country: Japan, China, India, Australia & Rest of APAC
Globally North America is the largest market for pancreatic cancer. The prevalence of pancreatic cancer is more in North American countries with the U.S. having the highest number of pancreatic cancer patients in the world. Asia-Pacific is anticipated to be the fastest-growing region across the globe.
Major players that are influencing Asia-Pacific Pancreatic Cancer Market include Eli Lilly, Amgen, Inc., Celgene Corp., F. Hoffmann-La Roche, Clovis Oncology Inc., Pfizer, Novartis AG, Threshold Pharmaceuticals Inc., Aduro BioTech Inc., Infinity Pharmaceuticals Inc. and NewLink Genetics Corp.
Write your comments, customizing requirements and inquiries about this research report to firstname.lastname@example.org